Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8836900 | Surgery | 2018 | 7 Pages |
Abstract
Neoadjuvant peptide receptor radionuclide therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms in patients with high-risk features of recurrence seems to be beneficial, but well-designed and much larger prospective trials are needed to confirm the safety and the oncologic value of this approach.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Stefano Partelli, Emilio Bertani, Mirco Bartolomei, Carolina Perali, Francesca Muffatti, Chiara Maria Grana, Marco Schiavo Lena, Claudio Doglioni, Stefano Crippa, Nicola Fazio, Giuseppe Zamboni, Massimo Falconi,